BTIG Maintains Buy on Globus Medical, Raises Price Target to $75
Portfolio Pulse from Benzinga Newsdesk
BTIG analyst Ryan Zimmerman maintains a Buy rating on Globus Medical (NYSE:GMED) and raises the price target from $72 to $75.
July 15, 2024 | 5:05 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BTIG analyst Ryan Zimmerman maintains a Buy rating on Globus Medical and raises the price target from $72 to $75.
The raised price target and maintained Buy rating from a reputable analyst can positively influence investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100